AP
TEVA icon

Aspect Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Aspect Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69K Hold
50
– – ﹤0.01% 523
2026
Q1 		$1.51K Hold
50
– – ﹤0.01% 544
2025
Q4 		$1.56K Hold
50
– – ﹤0.01% 586
2025
Q3 		$1.01K Hold
50
– – ﹤0.01% 651
2025
Q2 		$838 Hold
50
– – ﹤0.01% 539
2025
Q1 		$769 Hold
50
– – ﹤0.01% 518
2024
Q4 		$1.1K Sell
50
-150
-75% -$2.73K ﹤0.01% 522
2024
Q3 		$3.6K Buy
+200
New +$3.5K ﹤0.01% 393

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Aspect Partners's TEVA Position: Q2 2026 in Review

Aspect Partners held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 50 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #523.

Aspect Partners first reported a position in TEVA in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.6K in Q3 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Aspect Partners held 50 shares of Teva Pharmaceuticals worth $1.69K as of Q2 2026.
  • Aspect Partners left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #523 holding.
  • Aspect Partners first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Aspect Partners's Teva Pharmaceuticals position peaked at $3.6K in Q3 2024.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.